Tesamorelin: Research Guide

What is tesamorelin?

Deep in your brain, a hormone called GHRH (growth hormone–releasing hormone) tells your pituitary gland when to release growth hormone. Tesamorelin is a lab-made version of GHRH. It has the same 44 amino acids, plus a small chemical “tail” added to one end [S1] that makes it more stable in the body [1].

Unlike most peptides on this site, tesamorelin is an approved prescription medicine. The US Food and Drug Administration (FDA) approved it in 2010 under the brand name Egrifta [2, S1]. It’s approved for one specific use: reducing excess belly fat in adults with HIV who have lipodystrophy, a change in where the body stores fat [S1].

Why does that matter? Some people on long-term HIV treatment build up visceral fat, the deep belly fat that wraps around the organs. That type of fat is linked to a higher risk of heart disease [3].

How does it work?

Instead of supplying growth hormone directly, tesamorelin works one step earlier. It binds the same receptors as the body’s own GHRH, prompting the pituitary gland to make and release more of its own growth hormone, in natural bursts [S1].

Growth hormone helps the body break down stored fat [S1], and it raises IGF-1, a related hormone that drives many of growth hormone’s effects. In a large trial, IGF-1 levels rose by about 81% [3].

The interesting part is where the fat loss happens. Tesamorelin mainly shrinks deep belly fat while leaving the fat just under the skin largely unchanged [4, 5].

What has research found?

These findings come from human trials, most of them randomized and placebo-controlled (compared with a dummy treatment).

Deep belly fat (the approved use)

• The landmark trial: In 412 people with HIV, daily tesamorelin injections for 26 weeks shrank visceral fat by about 15%, while it grew by 5% on placebo. Blood fats improved too, with triglycerides falling sharply [3].
• A second large trial: In 404 people, visceral fat fell about 11% at six months and about 18% for those who stayed on it for a year. Waist size and people’s satisfaction with how their belly looked also improved [4].
• The big picture: A 2026 analysis that pooled four trials (909 people) confirmed less deep belly fat, smaller waists, less trunk fat, and slightly more lean body mass [6].
• The catch: The benefits last only as long as treatment does. When people stopped, the belly fat came back [7].

Liver fat

Fatty liver disease is common in people with HIV, and tesamorelin may help. In a 2014 trial of 50 people, it reduced both belly fat and liver fat [8]. In a 2019 trial of 61 people with HIV and fatty liver disease, liver fat fell by about 37% in relative terms after a year. Over a third of treated patients (35%) got their liver fat back into the normal range, compared with just 4% on placebo [9]. It also worked in people taking modern HIV medicines called integrase inhibitors [10].

Muscle

Among people whose belly fat responded, tesamorelin also increased the size of trunk muscles and reduced the fat stored inside them [11].

Beyond HIV

• Obesity: In 60 adults with abdominal obesity and lower-than-normal growth hormone, a year of tesamorelin reduced deep belly fat, triglycerides, and a marker of inflammation. It also slightly reduced the thickness of artery walls, an early sign of heart disease risk [5].
• Thinking skills: In 152 older adults, some with mild memory problems, 20 weeks of tesamorelin improved “executive function,” skills like planning and switching between tasks, compared with placebo [1]. A 2025 trial in people with HIV, however, found no clear thinking benefit compared with usual care [12].

How strong is the evidence?

A few more things to keep in mind:

• Benefits stop when treatment stops. Belly fat returns after people quit [7].
• Results vary from person to person. People whose belly fat dropped the most also saw the biggest improvements in blood fats and blood sugar [14].
• Funding varies. The drugmaker sponsored some trials [15], but trials funded by the US National Institutes of Health have found benefits too [9].

Safety: what we know

• Common side effects: The most frequent are joint pain, redness and itching where it’s injected, pain in the arms or legs, swelling, and muscle aches [S1].
• Fluid retention: Growth hormone effects can cause swelling, joint pain, or carpal tunnel syndrome [S1].
• Blood sugar: Tesamorelin can affect how the body handles sugar, so the label advises monitoring [S1]. In trials, though, blood sugar generally didn’t worsen, including in a study of people with type 2 diabetes [3, 15].
• IGF-1 levels: Because tesamorelin raises IGF-1, doctors monitor it. The effects of keeping IGF-1 high for many years are unknown [S1]. European regulators flagged possible links to cancer and diabetic eye disease as a concern [S2].
• Who shouldn’t use it: People who are pregnant, have active cancer, or have a pituitary problem [S1].
• Stopping treatment: More people stopped tesamorelin than placebo because of side effects [3, 6].
• “Research” products: Tesamorelin sold online as a research chemical isn’t the regulated medicine, and what those products actually contain is uncertain [16].

Legal status

• United States: An FDA-approved prescription medicine (brand name Egrifta, including the Egrifta WR formulation) for reducing excess belly fat in adults with HIV-associated lipodystrophy. It’s not approved for weight loss [S1].
• Europe: Not approved. The company withdrew its European application in 2012, when the application also covered the UK, after regulators indicated that the benefits didn’t outweigh the risks [S2].
• Sports: Banned at all times by the World Anti-Doping Agency (WADA) as a growth hormone–releasing factor [S3].

The bottom line

Tesamorelin is the most thoroughly tested peptide on this site. It’s an approved medicine backed by large, placebo-controlled trials, and it reliably reduces deep belly fat and liver fat in people with HIV. Early studies hint at more, from healthier arteries in people with obesity to sharper thinking in older adults.

The open questions are big ones: whether these changes add up to fewer heart attacks, how well tesamorelin works outside HIV, and what years of use mean for the body. Outside its approved use, sports medicine reviews still consider it investigational [17]. Those questions are exactly what makes tesamorelin worth watching.